A real-world study designed to assess the efficacy of nine oral glucose-lowering drugs in reducing HbA1c levels in adult Asians with T2D showed that the initiation of oral glucose-lowering drugs led to a reduction in HbA1c, ranging from −0.3 to −1.1%, with more pronounced effects observed with dipeptidyl peptidase 4 (DPP-4) inhibitors (−0.7% to −0.9%) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (−0.6% to −1.0%) (51). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.